1. Home
  2. RECT vs SKYE Comparison

RECT vs SKYE Comparison

Compare RECT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rectitude Holdings Ltd

RECT

Rectitude Holdings Ltd

HOLD

Current Price

$1.81

Market Cap

53.6M

Sector

N/A

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.08

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RECT
SKYE
Founded
1997
2012
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.6M
44.9M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
RECT
SKYE
Price
$1.81
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
11.2K
260.6K
Earning Date
07-31-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$32,594,177.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.61
N/A
Revenue Growth
5.91
N/A
52 Week Low
$1.79
$1.09
52 Week High
$7.68
$5.75

Technical Indicators

Market Signals
Indicator
RECT
SKYE
Relative Strength Index (RSI) 27.15 34.16
Support Level $1.79 $1.10
Resistance Level $2.12 $1.27
Average True Range (ATR) 0.11 0.08
MACD 0.02 0.02
Stochastic Oscillator 9.09 13.24

Price Performance

Historical Comparison
RECT
SKYE

About RECT Rectitude Holdings Ltd

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: